Galapagos NV (GLPG) Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.
News about GLPG
If You're Thinking About Buying Gilead Sciences Stock, Now's the Time to Do It
Good things come to those who wait. But those who wait too long can miss out. I suspect that there are plenty of investors wondering when the best time is to buy Gilead Sciences (NASDAQ:GILD). The biotech stock isn't the growth story that it was a fe...Read More>>>
Why Vertex Pharmaceuticals Incorporated Stock Surged 14% Today
What happened Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were trading 14% higher as of 11 a.m. EDT on Friday. The nice jump for the biotech stock came after Galapagos N.V. (NASDAQ:GLPG) announced disappointing results Thursday eveni...Read More>>>
Bad News Delivers a Decisive Blow to Galapagos N.V.
Galapagos N.V. (NASDAQ:GLPG) is developing new triplet combination therapies with AbbVie (NYSE:ABBV) for cystic fibrosis that the two companies hope can challenge Vertex Pharmaceuticals (NASDAQ:VRTX) someday. Unfortunately, the results reported ye...Read More>>>
Somewhat Positive News Coverage Somewhat Unlikely to Impact GALAPAGOS NV/S (GLPG) Share Price
News stories about GALAPAGOS NV/S (NASDAQ:GLPG) have trended somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverag...Read More>>>
Gilead Sciences Leads Its First Step Toward Pipeline Recovery With Clinical Candidate Filgotinib
Recently, Gilead (GILD) and its partner Galapagos NV (GLPG) announced successful data from a phase 2 study treating patients with psoriatic arthritis. This will allow both companies to move the drug filgotinib forward to a late-stage study. This is o...Read More>>>